Company targets US metabolic health crisis, raising $3m via crowdfunding with additional investment from a16z and others.
Consumer metabolic health company Levels has announced a $10 million Series A extension to ramp adoption of its digital platform. The New York-based company aims to help users improve their metabolic health by providing personalized feedback based on a range of biomarkers, including real-time blood sugar data from the company’s continuous glucose monitors (CGMs), blood testing, nutritional intake and various lifestyle factors like sleep and exercise.
Currently boasting more than 60,000 users, the Levels app leverages more than 700 million glucose data points and hundreds of thousands of food logs to deliver personalized insights to its users. The app’s AI-powered food logging and macro tracking features are complemented by accountability tools that help users understand how their dietary and lifestyle choices affect their health.
Founded in 2019, Levels’ mission is driven by the alarming state of metabolic health in the United States. With over 128 million Americans affected by prediabetes or diabetes, and 84% of those with prediabetes unaware of their condition, the company aims to address this crisis through “biological observability.” By tracking biomarkers like glucose and providing real-time feedback on how diet and lifestyle choices impact health, the app empowers users to make informed decisions that can lead to significant improvements in their metabolic health.
“Simply tracking meals isn’t enough,” said Levels CEO Sam Corcos. “That’s why Levels goes beyond basic food logging to actually show you how these choices affect your health, and what you should do to achieve your goals. Our members see results.”
The latest funding round was supported by over 2,000 investors through a $3 million crowdfunding campaign, with additional investments from firms, including Long Journey and Andreessen Horowitz (a16z). This latest crowdfunding is the company’s second, having raised $5 million from members as part of its original $38 million Series A.
“Levels is an immediate answer for the metabolic health crisis, the defining health crisis of our era,” said a16z co-founder Marc Andreessen. “Both the health of our people and the fiscal solvency of our country are at stake – Levels is a case study of the application of technology to both.”
In addition to its consumer-facing efforts, Levels is conducting a large-scale research study, in collaboration with academic researchers, which aims to increase understanding of glucose patterns across various demographics, including different ages, sexes and races. The study will explore how lifestyle choices influence these patterns and, ultimately, to improve metabolic health outcomes on a larger scale.
